RT Journal Article
SR Electronic
T1 Reversing fibrosis in metabolic dysfunction–associated steatohepatitis—beyond telling patients to lose weight
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 279
OP 286
DO 10.3949/ccjm.93a.25082
VO 93
IS 5
A1 Sierra, Leandro
A1 Liu, Lily
A1 Khurana, Akash
A1 Patel, Roma
A1 Chatterjee, Arjun
A1 Firkins, Stephen
A1 Simons-Linares, Roberto
YR 2026
UL http://www.ccjm.org/content/93/5/279.abstract
AB To reverse fibrosis in late-stage metabolic dysfunction–associated steatohepatitis (MASH), guidelines recommend that patients shed at least 10% of their body weight. However, losing this much weight remains a challenge for most patients, especially with lifestyle modifications alone. Moreover, not all patients with MASH are overweight or obese. This review summarizes pharmacologic, surgical, and bariatric endoscopic treatments for MASH to guide primary care physicians and internists.